MARKET

BDSX

BDSX

BIODESIX INC
NASDAQ

Real-time Quotes | Nasdaq Last Sale

19.30
+0.26
+1.37%
Opening 10:45 04/14 EDT
OPEN
19.04
PREV CLOSE
19.04
HIGH
19.30
LOW
18.66
VOLUME
1.85K
TURNOVER
--
52 WEEK HIGH
31.99
52 WEEK LOW
10.85
MARKET CAP
509.92M
P/E (TTM)
-0.4475
1D
5D
1M
3M
1Y
5Y
Biodesix Saturday Morning Announced New Data On Proteomic Profiling Presented Atk American Association For Cancer Research Apr. 10
Biodesix, Inc. (NASDAQ:BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that three abstracts from multiple clinical studies will be showcased at the 2021 American
Benzinga · 2d ago
Biodesix Releases New Data at AACR on Proteomic Profiling to Help Guide Physician Treatment Strategies for NSCLC Patients
Biodesix releases new data at AACR annual meeting on the use of proteomic profiling to help guide physician treatment strategies for NSCLC patients.
Business Wire · 4d ago
The Daily Biotech Pulse: Illumina Lights Up, Cara Soars On Index Inclusion, Novavax Starts Crossover Vaccine Study, Turning Point Data Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 5)
Benzinga · 04/06 12:04
Biodesix Announces Issuance of Two US Patents
Diagnostic Test and Novel Methodologies Designed to Guide Patient Assessment and Treatment Strategies Biodesix, Inc. (NASDAQ:BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease,
Benzinga · 04/06 10:16
BRIEF-Biodesix Announces Issuance Of Two U.S. Patents, Expands Coverage Of Diagnostic Methods To Improve Care For Cancer Patients
reuters.com · 04/06 10:03
Biodesix Announces Issuance of Two U.S. Patents, Expands Coverage of Diagnostic Methods to Improve Care for Cancer Patients
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that the United States Patent...
BusinessWire - BZX · 04/06 10:00
Illumina upgraded at Canaccord Genuity with readthrough to other firms on FTC Challenge
The challenge by the U.S. Federal Trade Commission to block the proposed acquisition of Grail by Illumina ([[ILMN]] +4.0%) led to a ~6.6% sell-off of the stock yesterday.Citing a brighter
Seekingalpha · 03/31 14:51
BRIEF-Biodesix Announces Closing Of New $30 Mln Term Loan
reuters.com · 03/23 20:03
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BDSX. Analyze the recent business situations of BIODESIX INC through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BDSX stock price target is 28.00 with a high estimate of 31.00 and a low estimate of 25.00.
EPS
Institutional Holdings
Institutions: 47
Institutional Holdings: 3.76M
% Owned: 14.25%
Shares Outstanding: 26.42M
TypeInstitutionsShares
Increased
0
0
New
47
3.76M
Decreased
0
0
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Healthcare Facilities & Services
+1.06%
Healthcare Providers & Services
+0.96%
Key Executives
Chairman/Director
Robert Cawthorn
Chief Executive Officer/Director
David Brunel
Founder/Chief Technology Officer
Heinrich Roder
Chief Financial Officer/Primary Contact
Robin Cowie
Chief Accounting Officer
Ryan Siurek
Other
Paul Beresford
No Data
About BDSX
Biodesix, Inc. is a United States-based company engaged in developing and commercializing blood-based diagnostic tests for oncology. The Company’s product Biodesix Lung Reflex integrates genomic and proteomic blood-based results to reveal both sides of lung cancer. Its GeneStrat test offers blood-based mutation results within 72 hours for patients with non-small cell lung cancer (NSCLC). Its VeriStrat testing provides blood-based predictive and prognostic proteomic information with (NSCLC) who test negative for estimated glomerular filtration rate (EGFR) mutations (EGFR wild-type) or whose EGFR mutation status is unknown.

Webull offers kinds of Biodesix Inc stock information, including NASDAQ:BDSX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BDSX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BDSX stock methods without spending real money on the virtual paper trading platform.